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The effect of intravitreal bevacizumab on visual acuity in exudative form of      
age-related macular degeneration treatments  
 
Učinak intravitrealne primjene bevacizumaba na vidnu oštrinu u eksudativnoj formi liječ nja                    






The aim of the research is to determine whether intravitreal bevacizumab improves the visual acuity 
significance in treatment of patients with exudative form of age-related macular degeneration.  
Patients and methods: This study included 45 patients, 75 eyes with senile degeneration of the macula 
lutea, who were treated in Prim. dr. Abdulah Nakas General Hospital during the period from November 
2007 - November 2010. The criteria for inclusion of patients in the study were that they had clinical signs of 
age-related degeneration of macula lutea with diagnostic methods verifying the changes in the retina, and
aged between 55 and 75 years.  
Result: The average age of patients treated with bevacizumab was 71.27 years (71 years, 3 months and 7 
days). The study included 28 female patients and 17 male patients. There was a statistically significant 
difference (p <0.05) in visual acuity between any measurement period. The smallest difference was between 
4 and 6 months but still statistically significant. If we analyze the trend line, we can conclude thatit is 
logarithmic, which shows that there is a trend of improvement.  
Conclusion: The results of the application of bevacizumab intravitreally in age-related degeneration of 
the macula lutea showed that intravitreal bevacizumab for exudative form of age-related macular 
degeneration improved the visual function of patients, which significantly affected the extension of their 
active life expectancy. 




Cilj istraživanja je ustanoviti poboljšava li intravitrealna primjena Bevacizumaba vidnu oštrinu 
pacijenata pri liječenju eksudativne forme senilne makularne degeneracij .  
Ispitanici i metode: U ovu studiju je uključeno 45 pacijenata, 75 očiju, koji imaju senilnu degeneraciju 
makule lutee, a koji su tretirani u Općoj bolnici, "Prim. dr. Abdulah Nakaš'', u razdoblju od studenoga 2007. 
do studenoga 2010. godine. Kriterij za uključenje pacijenata u studiju su bili pacijenti koji imaju kliničke 
simptome senilne degeneracije makule lutee s dijagnostičkim metodama verificiranim promjenama na retini, 
starosne dobi između 55 i 75 godina.  
Rezultat: Prosječna dob pacijenata tretiranih Bevacizumabom je 71,27 godina (71 godina, 3 mjeseca i 7 
dana). U studiju je uključeno 28 pacijenata ženskoga spola, te 17 pacijenata muškoga spola. Postoji 
statistički značajna razlika (p < 0,05) za vidnu oštrinu između bilo kojeg razdoblja mjerenja. Razlika je 
najmanja između 4 i 6 mjeseci, ali je i dalje statističk  značajna. Ako analiziramo liniju trenda možemo 
zaključiti da je ona logaritamska, odnosno pokazuje da postoji trend poboljšanja.  
Zaključak: Na osnovu dobijenih rezultata u primjeni Bevacizumaba intravitrealno kod senilne 
degeneracije makule lutee, utvrđeno je da intravitrealna primjena Bevacizumaba kod eksudativne forme 
senilne makularne degeneracije poboljšava vidne funkcije pacijenata, što znač jno utječe na produljenje 
njihove aktivne životne dobi. 
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Senile macular degeneration, in the world today, is 
a leading cause of vision impairment and blindness of 
the elderly population. Dry senile degeneration is a 
lighter form of macular degeneration, and the 
preliminary stage of development of severe exudative 
form.We are trying to maintain visual function by 
combining antioxidant therapy, argon laser photo-
coagulation PDT, Kenalog and inhibitors of vascular 
endothelial growth factor. 
After the injection of bevacizumab, some patients 
can expect improved vision, and some the slowing 
down or stopping of further vision deterioration in the 
eye of the affected, which depends on the duration of 
the illness. 
 
Growth Factor Blockers Therapy (anti-VEGF) 
 
The most modern and most recent AMD treatment 
modality involves the application of drugs directly 
injected in the vitreous area of the eye.1,2 
The following are used:  
- Avastin (Bevacizumab) 1.25 mg (0.05 ml) in 
three doses every two months. 
- Lucentis (Ranibizumab) 0.5 mg 1x a month 
for three months. 
- Macugen (Pegaptanib sodium) 0.3 mg in 




The aim of the research is to determine whether 
intravitreal bevacizumab improves the visual acuity 
significance in the treatment of patients with 
exudative form of age-related macular degeneration. 
 
Material and methods 
 
The study was conducted as a retrospective 
prospective clinical, manipulative control study. This 
study included 45 patients, 75 eyes with senile 
degeneration of the macula lutea, who were treated in 
"Prim. dr. Abdulah Nakas" General Hospital during 
the period from November 2007 – November 2010. 
The criteria for the inclusion of patients in the study 
were that the patients had clinical signs of age-related 
degeneration of macula lutea with diagnostic methods 
verifying the changes in the retina, and aged between 
55 and 75. The criteria for exclusion of the patients 
from the study: patients who had some other form of 





The intravitreal injection of Bevacizumab represent 
direct application of the medicine in the eye in a spot 
where the highest concentration and the strongest 
effect of the medicine is ensured.3,4,5 1.25 mg beva-
cizumab intravitreally (0.05 ml) is applied. 
The procedure is virtually painless, because a very 
thin and small 27 G needle is used, and the eye is 
previously anaesthetized by anesthetic drops, salt 
tetracaine 2x. The procedure is performed in the 
operating room due to complete sterility. It is 
measured by caliper, and it is given 3.5 mm from the 
limbus through the pars plana. 
In the first few days after the surgery, the patient 
can see floaters floating before the eye. Over time, 
usually in 1-3 months, the cure dissolves completely. 
The following complications may occur in a small 
percentage: 
- suffusions in the bulbar conjunctiva6,7 
- bleeding (haemophthalmus)8,9 
- increased intraocular pressure10,11 
- peeling of the internal membrane of the 
eye12,13 
- infection (endophthalmitis)14,15,16 




After the application of the drug, patients use 
antibiotic drops Tobrex salt 4x for five days.The 
patients are told that they will see floaters floating 
before the eye in the first few days after surgery. It is 
a remedy in the vitreous of the eye that quickly settles 
to the bottom of the eyeball, and it does not cause ny 




The visual acuity for distance is examined in all 
patients with a correction before giving bevacizumab, 
2 months after the application of the first dose, 4 
months after the application of the second dose, and 6 




Bevacizumab treatment was provided to 45 
patients, 75 eyes. Of these, 36 patients were treated 
for the right eye and 39 were treated for the left eye. 
In 30 patients, both eyes were treated with 
bevacizumab, in 6 patients just the right eye, and in 9 
patients only the left eye were treated (Table 1). 
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Table 1 Avastin application 








36 39 75 
 
Table 2 Gender and age structure 












28 17 45 
Age 
Starost 
71.18 71.41 71.27 
 
The average age of the patients was 71.27 years 
(Table 2). There was a statistically significant 
difference (p < 0.05) in visual acuity between any 
measurement period. The smallest difference was 
between 4 and 6 months, but it was still statistically 
significant. If we analyze the trend line, we can 
conclude that the trend line is logarithmic, and that it 
shows a decreasing trend of improvement between 
the second and third doses of bevacizumab (Table 3). 
 
Table 3 Average visual acuity 
Tablica 3. Prosječna oštrina vida 
 











0.16 0.21 0.25 0.26 
 
Table 4 Visual acuity 
Tablica 4. Oštrina vida 
 
Period of use 
Vrijeme uporabe 
VOD VOS 
Before Avastin therapy 
Prije terapije Avastinom 
0.15 0.17 
After the first dose 
Nakon prve doze 
0.21 0.21 
After the second dose 
Nakon druge doze 
0.26 0.24 
After the third dose 






This study included 45 patients who were treated 
in the Ophthalmology Department of Prim dr Abdulah 
Nakas General Hospital Bevacizumab treatment was 
provided to 45 patients, 75 eyes. Of these, 36 patients 
were treated on the right eye and 39 on the left ey. In 
30 patients both eyes were treated with bevacizumab, 
in 6 patients just the right eye, and in 9 just the left eye. 
The average age of patients treated with bevaci-
zumab was 71.27 years (71 years, 3 months and 7 
days). Avastin treatment is safe and effective for 
exudative AMD. It is not necessary to give an injection 
every month, the effect of the injection lasts for at least 
eight weeks. The average age of patients was 74.3 
years. Visual acuity improved from 0.08 to 0.2, and 
there is a reduction in central retinal thickness.19 
Lazic, Gabric reported patients with average age 
74.8 (61-85) years, increase in visual acuity of 1.29 
lines, p = 0.001.20 Ruppenstein at al study included 73 
eyes that were treated with 1.25 mg of Avastin 
intravitreally. After 30 weeks, visual acuity increased 
by one line.21 Intravitreal application of Avastin led to 
a significant improve-ment in visual acuity of 2.2 
lines.22 
There was a statistically significant difference (p < 
0.05) in visual acuity between any measurement 
period. The smallest difference was between 4 and 6 
months, but still statistically significant. Carneiro and 
colleagues, best corrected visual acuity was improved 
and central retinal thickness decreased.23Weigert and 
colleagues, visual acuity improved by 2.2 lines at 6 
months follow-up.24Subramanian and associates, visual 
acuity improved by 2 lines after a year of monitoring.25 
Singh and colleagues examined visual acuity in 73 
eyes during a period of 6 months. After three months, 
visual acuity improved by 1 line, and after 6 months by 
2 lines.26Wolfgang and associates, in 18 patients (56%) 
visual acuity improved by 3 lines, in 9 patients (28%) 
visual acuity did not change and in 5 cases (16%) there 




The study included a total of 45 patients, 75 eyes. 
Of these, 17 patients were male and 28 female 
patients. 30 patients received bevacizumab in both 
eyes, and 15 patients in one eye. 36 right and 39 left 
eyes were treated. The age of the patients was 71.27 
years. 
Visual acuity was with statistically significant 
difference in any measurement period. Visual acuity 
improved by 1 line, from 0.15 to 0.25. Based on the 
results obtained in the application of bevacizumab 
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intra-vitreally in age-related degeneration of macul  
lutea, the following conclusion is derived: The first 
application of intravitreal bevacizumab for exudative 
form of age-related macular degeneration improved 
visual function of patients, which significantly 
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